To include your compound in the COVID-19 Resource Center, submit it here.

ABT-450 plus ritonavir/ombitasvir: Phase II/III data

Data from 63 patients co-infected with HCV genotype 1 and HIV with or without compensated liver cirrhosis in part 1 of the 2-part, open-label, U.S. Phase II/III TURQUOISE-I trial showed that AbbVie's all-oral 3D regimen -- comprising co-administration with once-daily 150 mg ABT-450 plus

Read the full 444 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers